Developing differentiated medicines

for devastating diseases including inflammatory & immunological conditions, intractable cancers, lymphatic & GI diseases & neurological & neuropsychological disorders

Focus on the Brain Immune Gut (BIG) Axis

24 products and product candidates

12 are clinical stage

2 granted FDA clearance & European marketing authorization

Relationships with several pharma companies

or their investment arms

Team of world-class scientists and industry leaders


PureTech's Components of Value

 

Learn more about our unique discovery process

Wholly Owned Pipeline

Our programs
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
LYT-100
Deupirfenidone
Lymphatic flow disorders, incl. lymphedema
Initiation of Phase 2a POC study in H2 2020
LYT-100
Deupirfenidone
Long COVID1 respiratory complications & related sequelae
Initiation of Phase 2 study in H2 2020
LYT-100
Deupirfenidone
Other fibrotic & inflammatory disorders, such as IPF
LYT-200
Anti-Galectin-9 MAb
Solid tumors
IND & initiation of Phase 1 study in 2020
LYT-210
Anti-Delta-1 MAb
Solid tumors
LYT-300
Oral Allopregnanolone
Neurological indications

Cash at Puretech Parent Level

Founded Entities

1. Funding figure includes private equity financings, public offerings or grant awards. Funding figure excludes upfront payments and future milestone considerations received in conjunction with partnerships and collaborations such as those with Roche, Boehringer Ingelheim, Imbrium Therapeutics L.P., Shionogi & Co., Ltd. or Eli Lilly. Funding figure assumes all future tranches are funded in the Vor Series B financing round. Calculated as of January 1, 2017 to June 30, 2020.

2. PureTech Level Cash Reserves at September 30, 2020 represent cash balances and short-term investments held at PureTech Health LLC, PureTech Management, Inc., PureTech Health PLC, PureTech Securities Corporation of $372.0 million and held at PureTech LYT Inc., our internal pipeline, of $15.2 million, all of which are wholly owned entities of PureTech, excluding cash balances and short-term investments of $38.3 million held at Controlled Founded Entities which are not wholly owned.

Publications
Internal Pipeline
PureTech's Lymphatic Leap
Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

CD4(+) T regulatory cells (T(regs)), which express the Foxp3 transcription factor, play a critical role in the maintenance of immune homeostasis. Here, we show that in mice, T(regs) were most abundant in the colonic mucosa.

Full Article

Vedanta
Science: The Gut’s Clostridium Cocktail
Press releases
2020-11-11
PureTech Founded Entity Vor Biopharma Announces Exclusive License of Clinical-Stage CD33 CAR-T from National Cancer Institute

Continue

Press releases
2020-11-05
PureTech to Present at 29th Annual Credit Suisse Virtual Healthcare Conference

Continue

Press releases
2020-11-03
PureTech Founded Entity Gelesis Presents Three Poster Presentations at ObesityWeek® 2020

Continue